Ownership and insider activity for Bionano Genomics, Inc. (BNGO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles.
Price
| Price | $1.51 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-04 | Luderer Albert | P-Purchase | 4,000 | $5K |
| 2026-08-21 | Luderer Albert | P-Purchase | 4,000 | $5K |
| 2026-08-03 | Adamchak Mark | A-Award | 5,000 | $6K |
| 2026-08-03 | Dixon Jonathan V. | A-Award | 15,000 | $17K |
| 2026-08-03 | OLDAKOWSKI MARK | A-Award | 15,000 | $17K |
| 2026-08-03 | Hastie Alex Reid | A-Award | 54,000 | $60K |
| 2026-08-03 | OLDAKOWSKI MARK | 15,000 | $17K | |
| 2026-08-03 | Adamchak Mark | 5,000 | $6K | |
| 2026-08-03 | Hastie Alex Reid | 54,000 | $60K | |
| 2026-08-03 | Dixon Jonathan V. | 15,000 | $17K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.2M | $1.0M | $16.5M | $17.3M | $38.4M | $24.6M | $5.1M | $17.9M | $9.2M | $3.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $226.0M | $108.1M | $48.8M | $302000 | $10.3M |
| Receivables | $1.8M | $3.4M | $4.5M | $6.3M | $2.8M | $5.3M | $7.5M | $9.7M | $4.8M | $5.2M |
| Inventory | $1.8M | $1.7M | $1.1M | $3.4M | $3.3M | $12.4M | $29.8M | $22.9M | $11.1M | $5.4M |
| Total Current Assets | $10.7M | $7.1M | $23.0M | $28.3M | $46.8M | $272.4M | $157.3M | $140.1M | $39.5M | $45.4M |
| Property, Plant & Equipment | $4.1M | $3.0M | $1.8M | $1.9M | $4.9M | $20.9M | $29.0M | $32.5M | $24.3M | $21.2M |
| Goodwill | 0 | 0 | 0 | 0 | $7.2M | $56.2M | $77.3M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $1.5M | $26.8M | $41.1M | $34.0M | $9.7M | $4.3M |
| Total Assets | $14.8M | $10.1M | $24.8M | $30.2M | $60.5M | $377.1M | $307.5M | $214.4M | $76.7M | $73.6M |
| Accounts Payable | $792332 | $2.3M | $1.4M | $2.7M | $2.9M | $10.8M | $12.5M | $10.4M | $7.0M | $5.6M |
| Short-term Debt | $587131 | $6.7M | 0 | $20.1M | 0 | 0 | 0 | $69.8M | $20.4M | 0 |
| Total Current Liabilities | $9.4M | $16.7M | $4.5M | $26.4M | $8.9M | $21.8M | $35.9M | $100.0M | $37.3M | $22.9M |
| Long-term Debt | $6.0M | 0 | $9.0M | 0 | $16.3M | 0 | 0 | 0 | 0 | $6.0M |
| Total Liabilities | $42.0M | $60.4M | $14.7M | $26.6M | $25.4M | $40.0M | $58.1M | $118.2M | $41.3M | $29.2M |
| Retained Earnings | -$30.9M | -$54.3M | -$72.8M | -$102.6M | -$143.7M | -$216.1M | -$348.7M | -$581.2M | -$693.2M | -$719.6M |
| Total Equity | -$27.3M | -$50.2M | $10.1M | $3.6M | $35.1M | $337.1M | $249.4M | $96.2M | $35.4M | $44.4M |
| Total Debt | $6.6M | $6.7M | $9.0M | $20.1M | $16.3M | $10.7M | $11.7M | $79.4M | $27.3M | $6.9M |
| Net Debt | $1.4M | $5.7M | -$7.5M | $2.8M | -$22.1M | -$239.9M | -$101.5M | $12.6M | $17.8M | -$6.3M |
| Working Capital | $1.4M | -$9.5M | $18.5M | $1.9M | $37.8M | $250.6M | $121.4M | $40.1M | $2.1M | $22.4M |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 2.48 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -14.26 |
Profitability
| Return on Equity | -78.78% |
| Return on Invested Capital | -83.76% |
| Return on Assets | -67.58% |
| Gross Margin | 47.50% |
| Operating Margin | -106.67% |
| Net Margin | -106.58% |
Related companies: AIM · BNBX · GBS · KTTA · MYNZ · NDRA · POAI
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BNGO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks